within Pharmacolibrary.Drugs.ATC.C;

model C10AB12
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.99,
    Cl             = 1.1166666666666668e-05,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0135,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.021666666666666667,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.019399999999999997,
    k12             = 0.66,
    k21             = 0.66
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AB12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pemafibrate is a novel selective peroxisome proliferator-activated receptor alpha (PPARα) modulator (SPPARMα) used for the treatment of dyslipidemia, especially to lower triglyceride levels. It is approved in Japan for clinical use but is not widely approved in the United States or Europe as of 2024.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from healthy Japanese adult males after oral administration of pemafibrate (0.2 mg).</p><h4>References</h4><ol><li><p>Ogawa, SI, et al., &amp; Yamazaki, H (2019). Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator, in rats and monkeys. <i>Biopharmaceutics &amp; drug disposition</i> 40(1) 12–17. DOI:<a href=\"https://doi.org/10.1002/bdd.2165\">10.1002/bdd.2165</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30517973/\">https://pubmed.ncbi.nlm.nih.gov/30517973</a></p></li><li><p>Tomlinson, B, et al., &amp; Lam, CWK (2020). Pharmacokinetics of current and emerging treatments for hypercholesterolemia. <i>Expert opinion on drug metabolism &amp; toxicology</i> 16(5) 371–385. DOI:<a href=\"https://doi.org/10.1080/17425255.2020.1749261\">10.1080/17425255.2020.1749261</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32223657/\">https://pubmed.ncbi.nlm.nih.gov/32223657</a></p></li><li><p>Ogawa, SI, et al., &amp; Yamazaki, H (2020). Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1. <i>Drug metabolism and pharmacokinetics</i> 35(4) 354–360. DOI:<a href=\"https://doi.org/10.1016/j.dmpk.2020.03.005\">10.1016/j.dmpk.2020.03.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32601018/\">https://pubmed.ncbi.nlm.nih.gov/32601018</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AB12;
